Stocks
KV PharmaceuticalsKVPHQ
HealthcarePharmaceuticals
A specialty pharmaceutical company that developed and marketed Makena, a drug designed to prevent preterm births. It filed for Chapter 11 bankruptcy in 2017 after facing generic competition and legal challenges over the drug's pricing. Investors tracked it for its high-risk, high-reward profile in the biotech space.
Congressional Interest in KV Pharmaceuticals (KVPHQ)
1 member of Congress has disclosed 1 trade in KV Pharmaceuticals (KVPHQ), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading KVPHQ?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-04-11 | Harold Dallas Rogers | sell | $1K-$15K |